ALNYLAM PHARMACEUTICALS, INC. (ALNY) Free cash flow 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$465.4MFY2025 · since FY2016: -$372.3M → $465.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $465.4M | +1192.7% |
| FY2024 | -$42.6M | -201.5% |
| FY2023 | $41.9M | +106.8% |
| FY2022 | -$613.3M | +14.6% |
| FY2021 | -$718.1M | -4.8% |
| FY2020 | -$685.3M | -63.7% |
| FY2019 | -$418.6M | +39.3% |
| FY2018 | -$689.5M | -41.6% |
| FY2017 | -$487.0M | -30.8% |
| FY2016 | -$372.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Gross marginALNY Operating incomeALNY Operating marginALNY Operating cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →